Holen Sie sich die Stockscreener-App
5.44
8.57%
-0.51
Vorhandelsmarkt:
5.27
-0.17
-3.13%
Schlusskurs vom Vortag:
$5.95
Offen:
$5.87
24-Stunden-Volumen:
169.13K
Relative Volume:
0.54
Marktkapitalisierung:
$120.10M
Einnahmen:
$66.59M
Nettoeinkommen (Verlust:
$-104.93M
KGV:
-1.099
EPS:
-4.95
Netto-Cashflow:
$-96.48M
1W Leistung:
-3.37%
1M Leistung:
+15.01%
6M Leistung:
-51.69%
1J Leistung:
-64.14%
1-Tages-Spanne:
$5.44
$5.87
1-Wochen-Bereich:
$5.44
$6.23
52-Wochen-Spanne:
$4.09
$17.23
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Vergleichen Sie ENTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
5.44 | 120.10M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
| 2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
| 2018-12-13 | Eingeleitet | Berenberg | Hold |
| 2018-06-06 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | Barclays | Underweight |
| 2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - Yahoo Finance
JMP Securities maintains Enanta stock with $21 target - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
(ENTA) Investment Report - news.stocktradersdaily.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025 - marketscreener.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire
Breakthrough RSV Treatment Achieves Double Success in Latest Clinical Trial - Stock Titan
(ENTA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Enanta stock hits 52-week low at $4.71 amid market challenges - Investing.com Canada
Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Enanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to Immunology By Investing.com - Investing.com Canada
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win - Law360
Enanta Reveals Latest Autoimmune Drug Progress: Key Presentation March 27 - StockTitan
How To Trade (ENTA) - Stock Traders Daily
Enanta Pharmaceuticals Reports Q1 EPS Loss of $1.05, Beating Est - GuruFocus.com
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13 - Business Wire
Insider Buying: Jay Luly Acquires 45,000 Shares of Enanta Pharma - GuruFocus.com
Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
(ENTA) Trading Advice - Stock Traders Daily
Market Watch Highlights: Enanta Pharmaceuticals Inc (ENTA) Ends on an Upturn Note at 8.30 - The Dwinnex
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.com - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to “Hold” at StockNews.com - Defense World
HC Wainwright Has Pessimistic Outlook of ENTA Q2 Earnings - MarketBeat
Enanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlook - MSN
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $17.25 - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Purchases $256,050.00 in Stock - MarketBeat
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to "Sell" at StockNews.com - MarketBeat
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns - Yahoo Finance
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock - Yahoo Finance
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Market Outperform" Rating from JMP Securities - MarketBeat
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry - Simply Wall St
Enanta Pharmaceuticals’ (ENTA) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright maintains $18 target on Enanta shares, affirms Buy - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Quarterly Earnings Results - MarketBeat
Enanta Pharmaceuticals Advances in Virology and Immunology - TipRanks
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock By Investing.com - Investing.com South Africa
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):